Abstract
Ultrafiltration provides a generic method to discover ligands for protein drug targets with millimolar to micromolar K d, the typical range of fragment-based drug discovery. This method was tailored to a 96-well format, and cocktails of fragment-sized molecules, with molecular masses between 150 and 300 Da, were screened against medical structural genomics target proteins. The validity of the method was confirmed through competitive binding assays in the presence of ligands known to bind the target proteins.
| Original language | English |
|---|---|
| Pages (from-to) | 1589-1595 |
| Number of pages | 7 |
| Journal | Analytical and Bioanalytical Chemistry |
| Volume | 401 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 2011 |
Bibliographical note
Funding Information:We thank Eric T. Larson for his critical review of the manuscript. This work was supported by National Institutes of Health grants P50GM64655 (SGPP), P01AI067921 (MSGPP), and AI34501.
Funding
We thank Eric T. Larson for his critical review of the manuscript. This work was supported by National Institutes of Health grants P50GM64655 (SGPP), P01AI067921 (MSGPP), and AI34501.
| Funders | Funder number |
|---|---|
| MSGPP | |
| National Institutes of Health (NIH) | P50GM64655, P01AI067921 |
| National Institute of Allergy and Infectious Diseases | R56AI034501 |
Keywords
- Compound library
- Fragment-based drug discovery
- Screening
- Ultrafiltration
ASJC Scopus subject areas
- Analytical Chemistry
- Biochemistry